カテゴリー： QYResearch, 世界

世界の二次性副甲状腺機能亢進薬市場

◆英語タイトル：Global Secondary Hyperparathyroidism Drug Market Professional Survey Report 2019
◆商品コード：DATA909X14807
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2019年11月20日（※2024年版があります。お問い合わせください）
◆ページ数：105
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医薬品・ヘルスケア
◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,500 ⇒換算￥518,000	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD5,250 ⇒換算￥777,000	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD7,000 ⇒換算￥1,036,000	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートは、二次性副甲状腺機能亢進薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、エボカルセト、LNP-1892、AJT-240、シナカルセト塩酸塩、CTA-091、その他に、用途別には、病院、診療所、その他にセグメント区分し、二次性副甲状腺機能亢進薬の世界市場を分析しました。

・エグゼクティブ・サマリー
・二次性副甲状腺機能亢進薬の世界市場概要
・二次性副甲状腺機能亢進薬の製造コスト構成分析
・二次性副甲状腺機能亢進薬の開発・製造工場分析
・主要メーカーの主な指標（生産能力、売上、価格分析）
・二次性副甲状腺機能亢進薬の地域別分析（生産、売上、主要メーカー、輸出・輸入）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・二次性副甲状腺機能亢進薬のセグメント分析（種類別）
（エボカルセト、LNP-1892、AJT-240、シナカルセト塩酸塩、CTA-091、その他）
・二次性副甲状腺機能亢進薬のセグメント分析（用途別）
（病院、診療所、その他）
・二次性副甲状腺機能亢進薬の主要メーカー別分析（生産拠点、製品概要、生産・売上実績）
（Deltanoid Pharmaceuticals Inc、EA Pharma Co Ltd、Lupin Ltd、Mitsubishi Tanabe Pharma Corp、OPKO Health Inc、Shire Plc、）
・二次性副甲状腺機能亢進薬の市場規模予測（2019年～2025年）
（北米、ヨーロッパ、中国、日本国内、東南アジア、インド）
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス（市場動向、機会、成長要因、課題、影響因子）
...

【レポートの概要】

The global Secondary Hyperparathyroidism Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Secondary Hyperparathyroidism Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Secondary Hyperparathyroidism Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Secondary Hyperparathyroidism Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Secondary Hyperparathyroidism Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Deltanoid Pharmaceuticals Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tanabe Pharma Corp
OPKO Health Inc
Shire Plc
…

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Evocalcet
LNP-1892
AJT-240
Cinacalcet Hydrochloride
CTA-091
Others

Segment by Application
Hospital
Clinic
Others

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Secondary Hyperparathyroidism Drug
1.1 Definition of Secondary Hyperparathyroidism Drug
1.2 Secondary Hyperparathyroidism Drug Segment by Type
1.2.1 Global Secondary Hyperparathyroidism Drug Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Evocalcet
1.2.3 LNP-1892
1.2.4 AJT-240
1.2.5 Cinacalcet Hydrochloride
1.2.6 CTA-091
1.2.7 Others
1.3 Secondary Hyperparathyroidism Drug Segment by Applications
1.3.1 Global Secondary Hyperparathyroidism Drug Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Secondary Hyperparathyroidism Drug Overall Market
1.4.1 Global Secondary Hyperparathyroidism Drug Revenue (2014-2025)
1.4.2 Global Secondary Hyperparathyroidism Drug Production (2014-2025)
1.4.3 North America Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.4 Europe Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.5 China Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.6 Japan Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.7 Southeast Asia Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)
1.4.8 India Secondary Hyperparathyroidism Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Secondary Hyperparathyroidism Drug
2.3 Manufacturing Process Analysis of Secondary Hyperparathyroidism Drug
2.4 Industry Chain Structure of Secondary Hyperparathyroidism Drug

3 Development and Manufacturing Plants Analysis of Secondary Hyperparathyroidism Drug
3.1 Capacity and Commercial Production Date
3.2 Global Secondary Hyperparathyroidism Drug Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Secondary Hyperparathyroidism Drug
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Secondary Hyperparathyroidism Drug Production and Capacity Analysis
4.2 Secondary Hyperparathyroidism Drug Revenue Analysis
4.3 Secondary Hyperparathyroidism Drug Price Analysis
4.4 Market Concentration Degree

5 Secondary Hyperparathyroidism Drug Regional Market Analysis
5.1 Secondary Hyperparathyroidism Drug Production by Regions
5.1.1 Global Secondary Hyperparathyroidism Drug Production by Regions
5.1.2 Global Secondary Hyperparathyroidism Drug Revenue by Regions
5.2 Secondary Hyperparathyroidism Drug Consumption by Regions
5.3 North America Secondary Hyperparathyroidism Drug Market Analysis
5.3.1 North America Secondary Hyperparathyroidism Drug Production
5.3.2 North America Secondary Hyperparathyroidism Drug Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Secondary Hyperparathyroidism Drug Import and Export
5.4 Europe Secondary Hyperparathyroidism Drug Market Analysis
5.4.1 Europe Secondary Hyperparathyroidism Drug Production
5.4.2 Europe Secondary Hyperparathyroidism Drug Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Secondary Hyperparathyroidism Drug Import and Export
5.5 China Secondary Hyperparathyroidism Drug Market Analysis
5.5.1 China Secondary Hyperparathyroidism Drug Production
5.5.2 China Secondary Hyperparathyroidism Drug Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Secondary Hyperparathyroidism Drug Import and Export
5.6 Japan Secondary Hyperparathyroidism Drug Market Analysis
5.6.1 Japan Secondary Hyperparathyroidism Drug Production
5.6.2 Japan Secondary Hyperparathyroidism Drug Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Secondary Hyperparathyroidism Drug Import and Export
5.7 Southeast Asia Secondary Hyperparathyroidism Drug Market Analysis
5.7.1 Southeast Asia Secondary Hyperparathyroidism Drug Production
5.7.2 Southeast Asia Secondary Hyperparathyroidism Drug Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Secondary Hyperparathyroidism Drug Import and Export
5.8 India Secondary Hyperparathyroidism Drug Market Analysis
5.8.1 India Secondary Hyperparathyroidism Drug Production
5.8.2 India Secondary Hyperparathyroidism Drug Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Secondary Hyperparathyroidism Drug Import and Export

6 Secondary Hyperparathyroidism Drug Segment Market Analysis (by Type)
6.1 Global Secondary Hyperparathyroidism Drug Production by Type
6.2 Global Secondary Hyperparathyroidism Drug Revenue by Type
6.3 Secondary Hyperparathyroidism Drug Price by Type

7 Secondary Hyperparathyroidism Drug Segment Market Analysis (by Application)
7.1 Global Secondary Hyperparathyroidism Drug Consumption by Application
7.2 Global Secondary Hyperparathyroidism Drug Consumption Market Share by Application (2014-2019)

8 Secondary Hyperparathyroidism Drug Major Manufacturers Analysis
8.1 Deltanoid Pharmaceuticals Inc
8.1.1 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.1.2 Deltanoid Pharmaceuticals Inc Product Introduction, Application and Specification
8.1.3 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 EA Pharma Co Ltd
8.2.1 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.2.2 EA Pharma Co Ltd Product Introduction, Application and Specification
8.2.3 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Lupin Ltd
8.3.1 Lupin Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.3.2 Lupin Ltd Product Introduction, Application and Specification
8.3.3 Lupin Ltd Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Mitsubishi Tanabe Pharma Corp
8.4.1 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.4.2 Mitsubishi Tanabe Pharma Corp Product Introduction, Application and Specification
8.4.3 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 OPKO Health Inc
8.5.1 OPKO Health Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.5.2 OPKO Health Inc Product Introduction, Application and Specification
8.5.3 OPKO Health Inc Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Shire Plc
8.6.1 Shire Plc Secondary Hyperparathyroidism Drug Production Sites and Area Served
8.6.2 Shire Plc Product Introduction, Application and Specification
8.6.3 Shire Plc Secondary Hyperparathyroidism Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served

9 Development Trend of Analysis of Secondary Hyperparathyroidism Drug Market
9.1 Global Secondary Hyperparathyroidism Drug Market Trend Analysis
9.1.1 Global Secondary Hyperparathyroidism Drug Market Size (Volume and Value) Forecast 2019-2025
9.2 Secondary Hyperparathyroidism Drug Regional Market Trend
9.2.1 North America Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.2 Europe Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.3 China Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.4 Japan Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.5 Southeast Asia Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.2.6 India Secondary Hyperparathyroidism Drug Forecast 2019-2025
9.3 Secondary Hyperparathyroidism Drug Market Trend (Product Type)
9.4 Secondary Hyperparathyroidism Drug Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Secondary Hyperparathyroidism Drug Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Secondary Hyperparathyroidism Drug
Table Global Secondary Hyperparathyroidism Drug Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Secondary Hyperparathyroidism Drug Production Market Share by Types in 2018
Figure Evocalcet Product Picture
Figure LNP-1892 Product Picture
Figure AJT-240 Product Picture
Figure Cinacalcet Hydrochloride Product Picture
Figure CTA-091 Product Picture
Figure Others Product Picture
Table Global Secondary Hyperparathyroidism Drug Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Secondary Hyperparathyroidism Drug Consumption Market Share by Applications in 2018
Figure Hospital
Figure Clinic
Figure Others
Figure Global Secondary Hyperparathyroidism Drug Revenue (Million USD) (2014-2025)
Figure Global Secondary Hyperparathyroidism Drug Production (K Pcs) (2014-2025)
Figure North America Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure Europe Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure China Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure Japan Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Figure India Secondary Hyperparathyroidism Drug Market Size (Million USD) (2014-2025)
Table Secondary Hyperparathyroidism Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Secondary Hyperparathyroidism Drug in 2018
Figure Manufacturing Process Analysis of Secondary Hyperparathyroidism Drug
Figure Industry Chain Structure of Secondary Hyperparathyroidism Drug
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Secondary Hyperparathyroidism Drug Manufacturing Plants Distribution
Table Secondary Hyperparathyroidism Drug Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Secondary Hyperparathyroidism Drug Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Secondary Hyperparathyroidism Drug Production (K Pcs) of Major Manufacturers (2014-2019)
Table Secondary Hyperparathyroidism Drug Production Market Share of Major Manufacturers (2014-2019)
Figure Secondary Hyperparathyroidism Drug Production Share by Manufacturers in 2018
Table Secondary Hyperparathyroidism Drug Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Secondary Hyperparathyroidism Drug Revenue Market Share of Major Manufacturers (2014-2019)
Figure Secondary Hyperparathyroidism Drug Revenue Share by Manufacturers in 2018
Table Secondary Hyperparathyroidism Drug Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Secondary Hyperparathyroidism Drug Production by Regions 2014-2019 (K Pcs)
Table Global Secondary Hyperparathyroidism Drug Production Market Share by Regions 2014-2019
Figure Global Secondary Hyperparathyroidism Drug Production Market Share by Regions in 2018
Table Global Secondary Hyperparathyroidism Drug Revenue by Regions 2014-2019 (Million USD)
Table Global Secondary Hyperparathyroidism Drug Revenue Market Share by Regions 2014-2019
Figure Global Secondary Hyperparathyroidism Drug Revenue Market Share by Regions in 2018
Table Global Secondary Hyperparathyroidism Drug Consumption by Regions 2014-2019 (K Pcs)
Table Global Secondary Hyperparathyroidism Drug Consumption Market Share by Regions 2014-2019
Figure North America Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure North America Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table North America Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Europe Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure China Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure China Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table China Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Japan Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure India Secondary Hyperparathyroidism Drug Production Growth Rate 2014-2019 (K Pcs)
Figure India Secondary Hyperparathyroidism Drug Revenue Growth Rate 2014-2019 (Million USD)
Table India Secondary Hyperparathyroidism Drug Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Secondary Hyperparathyroidism Drug Market Share by Application (2014-2019)
Figure Global Value (Consumption) Secondary Hyperparathyroidism Drug Market Share by Application (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Lupin Ltd Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Lupin Ltd Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Lupin Ltd Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Lupin Ltd Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure OPKO Health Inc Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table OPKO Health Inc Secondary Hyperparathyroidism Drug Main Business and Markets Served
Table Shire Plc Secondary Hyperparathyroidism Drug Production Sites and Area Served
Table Shire Plc Secondary Hyperparathyroidism Drug Product Introduction, Application and Specification
Table Shire Plc Secondary Hyperparathyroidism Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Shire Plc Secondary Hyperparathyroidism Drug Production Growth Rate (2014-2019)
Table Shire Plc Secondary Hyperparathyroidism Drug Production Market Share (2014-2019)
Figure Shire Plc Secondary Hyperparathyroidism Drug Revenue Market Share (2014-2019)
Table Shire Plc Secondary Hyperparathyroidism Drug Main Business and Markets Served
Figure Global Secondary Hyperparathyroidism Drug Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Secondary Hyperparathyroidism Drug Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Secondary Hyperparathyroidism Drug Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Secondary Hyperparathyroidism Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Secondary Hyperparathyroidism Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Secondary Hyperparathyroidism Drug by Type (2019-2025)
Table Global Consumption (K Pcs) of Secondary Hyperparathyroidism Drug by Application (2019-2025)
Table Secondary Hyperparathyroidism Drug Distributors List
Table Secondary Hyperparathyroidism Drug Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

【掲載企業】

Deltanoid Pharmaceuticals Inc、EA Pharma Co Ltd、Lupin Ltd、Mitsubishi Tanabe Pharma Corp、OPKO Health Inc、Shire Plc、

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の二次性副甲状腺機能亢進薬市場(Global Secondary Hyperparathyroidism Drug Market Professional Survey Report 2019)]についてメールでお問い合わせはこちらでお願いします。

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 GlobalResearch.jp